Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$149.76 USD

149.76
1,714,060

+5.62 (3.90%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $149.78 +0.02 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Illumina (ILMN) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks.com featured highlights include: Stoneridge, Illumina, TPI Composites and JD.com

by Zacks Equity Research

Zacks.com featured highlights include: Stoneridge, Illumina, TPI Composites and JD.com

Rimmi Singhi headshot

Let Go of These 4 Toxic Stocks Right Away

by Rimmi Singhi

Steer clear of toxic stocks like SRI, ILMN, TPIC and JD to safeguard your portfolio from losses.

New Strong Sell Stocks for October 19th

by Zacks Equity Research

ACCD, EAT, ILMN, MAXN, and TM have been added to the Zacks Rank #5 (Strong Sell) List on October 19, 2021

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Here's Why You Should Hold on to Illumina (ILMN) for Now

by Zacks Equity Research

Investors are optimistic about Illumina (ILMN) owing to its strategic partnerships and wider market adoption of its products.

Daniel Laboe headshot

Market Bears Take The Bulls By The Horns As Q4 Kicks Off

by Daniel Laboe

We are not out of the correction woods yet as mega-cap tech breaks below Friday's lows

Illumina (ILMN) Oncology Growth Aids Amid GRAIL Merger Hurdle

by Zacks Equity Research

Illumina (ILMN) is making progress outside the United States to ensure all expecting families have access to NIPT.

The Zacks Analyst Blog Highlights: Eli Lilly, Costco, Applied Materials, Illumina and Norfolk Southern Corp

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Eli Lilly, Costco, Applied Materials, Illumina and Norfolk Southern Corp

Sheraz Mian headshot

Top Stock Reports for Eli Lilly, Costco & Applied Materials

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Costco Wholesale Corporation (COST), and Applied Materials, Inc. (AMAT).

QGEN or ILMN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

QGEN vs. ILMN: Which Stock Is the Better Value Option?

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Illumina (ILMN), Merck Ink Cancer Companion Diagnostics Deal

by Zacks Equity Research

Illumina (ILMN) collaborated with Merck to develop and commercialize companion diagnostics to identify ovarian cancer patients with positive HRD status for treatment with LYNPARZA.

Illumina (ILMN), Grail Merger Sees Futher Regulatory Challenges

by Zacks Equity Research

According to Illumina (ILMN), GRAIL will continue to operate as a separate company until the ongoing regulatory review by the EC is completed.

Illumina (ILMN) Shares Slip on GRAIL Buyout Deal Completion

by Zacks Equity Research

Illumina (ILMN) acquisition of GRAIL will expand patient access to life-saving multi-cancer early-detection test.

If You Invested $1000 in Illumina 10 Years Ago, This Is How Much You'd Have Now

by Zacks Equity Research

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Looking for a Growth Stock? 3 Reasons Why Illumina (ILMN) is a Solid Choice

by Zacks Equity Research

Illumina (ILMN) possesses solid growth attributes, which could help it handily outperform the market.

Illumina (ILMN) Q2 Earnings Top Estimates, 2021 View Up

by Zacks Equity Research

Year-over-year improvement in segmental revenues in Q2 across all geographies exceeds Illumina's (ILMN) expectations.

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Illumina (ILMN) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Illumina (ILMN) delivered earnings and revenue surprises of 37.50% and 11.26%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Drug/Biotech Stocks Q2 Earnings Due on Aug 5: REGN, MRNA, ZTS, ILMN

by Zacks Equity Research

Let us take a look at what is in store for some of the drug/biotech stocks, which are scheduled to report on Aug 5.

AMN Healthcare (AMN) to Report Q2 Earnings: What to Expect?

by Zacks Equity Research

Continued strength in AMN Healthcare's (AMN) staffing services is expected to have driven up Q2 sales.

Quidel (QDEL) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Quidel (QDEL) is likely to have registered solid product sales during Q2 which are likely to have driven its overall top line.

What's in Store for Fulgent Genetics (FLGT) in Q2 Earnings?

by Zacks Equity Research

Fulgent Genetics' (FLGT) Q2 results are likely to reflect growth in areas like adult neurogenetics, hereditary cancer, hereditary cardiovascular genetics, reproductive health and sequencing as a service.

BD (BDX) Gears Up for Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Continued strength in BD's (BDX) Life Sciences segment is expected to have driven up Q3 sales.